Treating Drug-Resistant Tuberculosis
Treating Drug-Resistant TuberculosisSkip to the navigationTopic Overview People infected with tuberculosis (TB) bacteria that are
antibiotic-resistant need special treatment programs. People with a weakened
immune system are more likely to get drug-resistant
TB. These include people infected with HIV or people who have had an organ
transplant. Treatment usually involves at least four medicines.footnote 1 - A treatment program using four to six medicines appears to be
best. The choice of medicines depends on the results of
sensitivity testing.
- Most treatment
programs involve isoniazid, rifampin, and pyrazinamide, along with one to three
second-choice medicines.
- Second-choice medicines used to treat
drug-resistant TB usually have more side effects than the first-choice
medicines. Second-choice medicines include streptomycin, capreomycin,
ethionamide, kanamycin, ofloxacin, para-aminosalicylic acid, and
rifabutin.
- It is very important to take every dose of medicine.
So
directly observed therapy (DOT) usually is done.
During DOT, a health professional watches you take every dose of
medicine.
- Treatment is continued until TB bacteria can no longer be
found in two
sputum samples taken a month apart. This may take 18
months or longer in people with
multidrug-resistant TB (MDR-TB).
Some TB bacteria have become resistant to all of the antibiotics that are commonly used to treat TB. This is sometimes called totally resistant tuberculosis (TDR-TB).footnote 2 A TB infection of this type is very difficult to treat. ReferencesCitations- American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2003). Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4): 603-662.
- Cegielski P, et al. (2012). Challenges and controversies in defining totally drug-resistant tuberculosis. Emerging Infectious Diseases [Internet], November. Available online: http://wwwnc.cdc.gov/eid/article/18/11/12-0526_article.htm.
CreditsByHealthwise Staff Primary Medical ReviewerE. Gregory Thompson, MD - Internal Medicine Specialist Medical ReviewerR. Steven Tharratt, MD, MPVM, FACP, FCCP - Pulmonology, Critical Care Medicine, Medical Toxicology Current as ofMarch 3, 2017 Current as of:
March 3, 2017 American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2003). Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4): 603-662. Cegielski P, et al. (2012). Challenges and controversies in defining totally drug-resistant tuberculosis. Emerging Infectious Diseases [Internet], November. Available online: http://wwwnc.cdc.gov/eid/article/18/11/12-0526_article.htm. Last modified on: 8 September 2017
|
|
|
|
|
|